OncoK9: The Liquid Biopsy Cancer Screen for Dogs

As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.

Cancer is by far the single most common cause of death in adult dogs. Like humans, dogs have a 1 in 3 lifetime risk of getting cancer, and approximately 6 million dogs are newly diagnosed with cancer each year in the United States. Older dogs and certain breeds have a higher lifetime risk of cancer and/or have a higher risk of being diagnosed at an earlier age. Cancer in dogs is often diagnosed at an advanced stage, when treatment options are limited, and chances of long-term control or cure are low. Each year, cancer cuts short the lives of many dogs who might have enjoyed many healthy years with their families had the disease been detected earlier.

Each cell in a dog’s body contains billions of DNA “letters” that make up the dog’s genome. Cancer develops as a result of the successive accumulation of genomic alterations (DNA mutations) over time. All cells release DNA fragments into the bloodstream. DNA released from cancer cells contains specific genomic alterations associated with cancer that can be detected by liquid biopsy with the OncoK9 test. (OncoK9 indicates whether cancer is currently present in the body; it does not indicate risk for future cancer development.)

OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using next-generation sequencing (NGS) technology. OncoK9 is intended for use in dogs who are at higher risk of cancer. The risk of cancer in dogs increases with age and is also increased in certain breeds. 

OncoK9 is recommended as an annual screening test for all dogs starting at 7 years of age and starting at younger ages for dogs belonging to breeds in which cancer tends to develop earlier in life.  OncoK9 is recommended as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings.

Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study
The international, multi-center clinical study demonstrated that OncoK9® – The Liquid Biopsy Test for Dogs™ can detect 30 different types of cancer with a simple blood draw. The CANDiD study included blood samples collected prospectively from more than 1,000 client-owned dogs at more than 40 clinical sites across the United States, Canada, Brazil, the Netherlands, France, and Hong Kong between 2019 and 2021.

Results of the CANDiD Study – the largest clinical validation study ever performed in veterinary cancer diagnostics – were recently published by PLOS ONE, a leading peer-reviewed journal.

Study: https://journals.plos.org/plos...

For more information, please see the website and video found at: https://petdx.com/pet-parents/.


1

2

Hours of Operation

Monday

9:00 AM - 6:00 pm

Tuesday

9:00 AM - 8:00 pm

Wednesday

9:00 AM - 6:00 pm

Thursday

9:00 AM - 8:00 pm

Friday

9:00 AM - 6:00 pm

Saturday

Closed

Sunday

Closed

Monday
9:00 AM - 6:00 pm
Tuesday
9:00 AM - 8:00 pm
Wednesday
9:00 AM - 6:00 pm
Thursday
9:00 AM - 8:00 pm
Friday
9:00 AM - 6:00 pm
Saturday
Closed
Sunday
Closed

Our Location

Contact Us

We look forward to hearing from you